Literature DB >> 29523504

Hepcidin agonists as therapeutic tools.

Carla Casu1, Elizabeta Nemeth2, Stefano Rivella1.   

Abstract

Hepcidin agonists are a new class of compounds that regulate blood iron levels, limit iron absorption, and could improve the treatment of hemochromatosis, β-thalassemia, polycythemia vera, and other disorders in which disrupted iron homeostasis causes or contributes to disease. Hepcidin agonists also have the potential to prevent severe complications of siderophilic infections in patients with iron overload or chronic liver disease. This review highlights the preclinical studies that support the development of hepcidin agonists for the treatment of these disorders.
© 2018 by The American Society of Hematology.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29523504      PMCID: PMC5909761          DOI: 10.1182/blood-2017-11-737411

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  54 in total

1.  Hepcidin as a therapeutic tool to limit iron overload and improve anemia in β-thalassemic mice.

Authors:  Sara Gardenghi; Pedro Ramos; Maria Franca Marongiu; Luca Melchiori; Laura Breda; Ella Guy; Kristen Muirhead; Niva Rao; Cindy N Roy; Nancy C Andrews; Elizabeta Nemeth; Antonia Follenzi; Xiuli An; Narla Mohandas; Yelena Ginzburg; Eliezer A Rachmilewitz; Patricia J Giardina; Robert W Grady; Stefano Rivella
Journal:  J Clin Invest       Date:  2010-11-22       Impact factor: 14.808

Review 2.  New strategies to target iron metabolism for the treatment of beta thalassemia.

Authors:  Paraskevi Rea Oikonomidou; Carla Casu; Stefano Rivella
Journal:  Ann N Y Acad Sci       Date:  2016-02-25       Impact factor: 5.691

Review 3.  β-thalassemia: a model for elucidating the dynamic regulation of ineffective erythropoiesis and iron metabolism.

Authors:  Yelena Ginzburg; Stefano Rivella
Journal:  Blood       Date:  2011-07-18       Impact factor: 22.113

Review 4.  β-thalassemias: paradigmatic diseases for scientific discoveries and development of innovative therapies.

Authors:  Stefano Rivella
Journal:  Haematologica       Date:  2015-04       Impact factor: 9.941

5.  Minihepcidins prevent iron overload in a hepcidin-deficient mouse model of severe hemochromatosis.

Authors:  Emilio Ramos; Piotr Ruchala; Julia B Goodnough; Léon Kautz; Gloria C Preza; Elizabeta Nemeth; Tomas Ganz
Journal:  Blood       Date:  2012-09-18       Impact factor: 22.113

6.  The gene encoding the iron regulatory peptide hepcidin is regulated by anemia, hypoxia, and inflammation.

Authors:  Gaël Nicolas; Caroline Chauvet; Lydie Viatte; Jean Louis Danan; Xavier Bigard; Isabelle Devaux; Carole Beaumont; Axel Kahn; Sophie Vaulont
Journal:  J Clin Invest       Date:  2002-10       Impact factor: 14.808

7.  Hepcidin in iron overload disorders.

Authors:  George Papanikolaou; Michalis Tzilianos; John I Christakis; Dionisios Bogdanos; Konstantina Tsimirika; Julie MacFarlane; Y Paul Goldberg; Nikos Sakellaropoulos; Tomas Ganz; Elizabeta Nemeth
Journal:  Blood       Date:  2005-01-25       Impact factor: 22.113

Review 8.  A Red Carpet for Iron Metabolism.

Authors:  Martina U Muckenthaler; Stefano Rivella; Matthias W Hentze; Bruno Galy
Journal:  Cell       Date:  2017-01-26       Impact factor: 41.582

9.  Liver iron concentrations and urinary hepcidin in beta-thalassemia.

Authors:  Raffaella Origa; Renzo Galanello; Tomas Ganz; Nicolina Giagu; Liliana Maccioni; Gavino Faa; Elizabeta Nemeth
Journal:  Haematologica       Date:  2007-05       Impact factor: 9.941

Review 10.  Hepcidin regulation in the anemia of inflammation.

Authors:  Chia-Yu Wang; Jodie L Babitt
Journal:  Curr Opin Hematol       Date:  2016-05       Impact factor: 3.284

View more
  32 in total

Review 1.  Liver iron sensing and body iron homeostasis.

Authors:  Chia-Yu Wang; Jodie L Babitt
Journal:  Blood       Date:  2018-11-06       Impact factor: 22.113

Review 2.  Iron metabolism under conditions of ineffective erythropoiesis in β-thalassemia.

Authors:  Stefano Rivella
Journal:  Blood       Date:  2018-11-06       Impact factor: 22.113

3.  Replacing the suppressed hormone: toward a better treatment for iron overload in β-thalassemia major?

Authors:  Domenico Girelli; Fabiana Busti
Journal:  Haematologica       Date:  2020-07       Impact factor: 9.941

4.  Iron, Hepcidin, and Death in Human AKI.

Authors:  David E Leaf; Mohan Rajapurkar; Suhas S Lele; Banibrata Mukhopadhyay; Emily A S Boerger; Finnian R Mc Causland; Michele F Eisenga; Karandeep Singh; Jodie L Babitt; John A Kellum; Paul M Palevsky; Marta Christov; Sushrut S Waikar
Journal:  J Am Soc Nephrol       Date:  2019-02-08       Impact factor: 10.121

5.  Dendritic cell-derived hepcidin sequesters iron from the microbiota to promote mucosal healing.

Authors:  Nicholas J Bessman; Jacques R R Mathieu; Cyril Renassia; Lei Zhou; Thomas C Fung; Keith C Fernandez; Christine Austin; Jesper B Moeller; Sara Zumerle; Sabine Louis; Sophie Vaulont; Nadim J Ajami; Harry Sokol; Gregory G Putzel; Tara Arvedson; Robbyn E Sockolow; Samira Lakhal-Littleton; Suzanne M Cloonan; Manish Arora; Carole Peyssonnaux; Gregory F Sonnenberg
Journal:  Science       Date:  2020-04-10       Impact factor: 47.728

6.  New potential players in hepcidin regulation.

Authors:  Maxwell Chappell; Stefano Rivella
Journal:  Haematologica       Date:  2019-09       Impact factor: 9.941

Review 7.  Inherited microcytic anemias.

Authors:  Maria Domenica Cappellini; Roberta Russo; Immacolata Andolfo; Achille Iolascon
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2020-12-04

8.  Up-regulation of the manganese transporter SLC30A10 by hypoxia-inducible factors defines a homeostatic response to manganese toxicity.

Authors:  Chunyi Liu; Thomas Jursa; Michael Aschner; Donald R Smith; Somshuvra Mukhopadhyay
Journal:  Proc Natl Acad Sci U S A       Date:  2021-08-31       Impact factor: 11.205

9.  Transferrin receptor 2 is a potential novel therapeutic target for β-thalassemia: evidence from a murine model.

Authors:  Irene Artuso; Maria Rosa Lidonnici; Sandro Altamura; Giacomo Mandelli; Mariateresa Pettinato; Martina U Muckenthaler; Laura Silvestri; Giuliana Ferrari; Clara Camaschella; Antonella Nai
Journal:  Blood       Date:  2018-09-12       Impact factor: 22.113

Review 10.  Novel Pathophysiological Mechanisms of Thrombosis in Myeloproliferative Neoplasms.

Authors:  Brandi N Reeves; Joan D Beckman
Journal:  Curr Hematol Malig Rep       Date:  2021-04-19       Impact factor: 4.213

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.